ESMO 2023: Looking Forward to Fresh Data for Advanced NSCLC

Julia Rotow, MD

October 12, 2023

Julia Rotow, MD, speculates on the expected wave of new data to be presented at ESMO 2023, and specifically on those studies that pertain to actionable targets in non–small cell lung cancer.

Beginning with the latest results regarding immunotherapy combinations for cancers with driver mutations, Dr Rotow proceeds to round out the scope of new therapeutic initiatives with mention of more recent modes of treatment, including antibody-drug conjugates (ADCs) as studied in the TROPION-Lung05 and HERTHENA-Lung01 trials, and, importantly, anticipates updates on the activity of ADCs on central nervous system metastases.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ESMO 2023: Looking Forward to Fresh Data for Advanced NSCLC - Medscape - Oct 12, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

ESMO 2023: Looking Forward to Fresh Data for Advanced NSCLC

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Julia Rotow, MD

Comments

Email This

Feedback